The journals published by ARAS PART MEDICAL INT PRESS endorse the guidelines of the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME) Policy Statement on Geopolitical Intrusion on Editorial Decisions, the Council of Science Editors’ White Paper on Promoting Integrity in Scientific Journal Publications and the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.
Submitting a manuscript to a journal published by ARAS PART MEDICAL INT PRESS implies that all contributors listed as authors have read and agreed to the content of the submitted work and that the submission observes the policies of the journal.
Ethics and consent
Every submission reporting a research must include a statement to verify that ethics approval was sought for the study (or a statement that it was not required and why), including the name of the ethics committee(s) or institutional review board(s), the reference number/ID of the approval(s), and a statement that participants gave informed consent before participating. Even when a study has been approved by a research ethics committee or institutional review board, editors may ask authors for more detailed information about the ethics of the work. Also, research involving human subjects, human tissue, or human data must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. Submissions may be declined if the journals’ editors come to conclusion that a research has not been carried out within an appropriate ethical framework. The editors may also contact the institutions’ ethics committee for further information in certain cases.
Allegations of publication misconduct, both before and after publication will be carefully inspected and we reserve the right to contact authors' institutions, funders, or regulatory bodies if necessary. If a conclusive evidence of misconduct is noticed, proper steps will be taken to correct the scientific record, which may include supplying a correction or retraction.
Authors are assumed that they are aware of publication ethics, specifically with regard to authorship, dual submission, plagiarism, figure manipulation, competing interests and compliance with standards of research ethics. In cases of suspected misconduct, COPE standards and practices will be followed and advice from the COPE forum will be ascertained.
Retrospective ethics approval
If a study has not been granted ethics committee approval prior to commencing, retrospective ethics approval usually cannot be obtained and it may not be possible to consider the submission for peer review. The decision on whether to proceed to peer review in such cases is at the discretion of the journals’ editors.
Patient consent and confidentiality
Any item submitted to the journals published by ARAS PART MEDICAL INT PRESS that contains personal medical information about an identifiable living individual requires patient’s explicit consent before it can be published. Consequently; all studied patients are required to sign an informed consent form after reading the studies’ information sheet.
If consent cannot be obtained because the patient cannot be traced in a study, then publication will be possible only if the information can be sufficiently anonymized. Anonymization means that neither the person nor anyone else could identify the individual with certainty.
If the patient is dead the authors should seek permission from a relative (as a matter of courtesy and medical ethics). If the relatives are not contactable, the journals will balance the worth whileness of the case, the likelihood of identification, and the likelihood of offence in decision to publish a submitted paper.
Images—such as x-rays, laparoscopic images, ultrasound images, pathology slides, or images of undistinctive parts of the body—may be used without consent so long as they are anonymized by the removal of any identifying marks and are not accompanied by text that could reveal the patients’ identity.
Research involving animals
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere when conducting research on animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
For experimental studies involving client-owned animals, authors must also document informed consent from the client or owner and adherence to a high standard (best practice) of veterinary care.
Based on the ICMJE recommendations a clinical trial is defined as “any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect, relationship between a health-related intervention and a health outcome.”
In agreement with the ICMJE’s recommendations, all journals published by ARAS PART MEDICAL INT PRESS will not consider reports of clinical trials unless they were registered prospectively before recruitment of any participants.
As a condition of consideration for publication, journals published by the ARAS PART MEDICAL INT PRESS require registration of all trials in a public registry of trials approved by the ICMJE (any registry that is a primary register of the WHO International Clinical Trials Registry Platform www.who.int/ictrp/network/primary/en/index.html).
The trial registration number and the date of registration should be included in the last line of the submission abstract.
Standards of reporting
Authors are encouraged to use the relevant research reporting guidelines for the study type provided by the EQUATOR Network when preparing their manuscript. Authors should adhere to these guidelines when drafting their manuscript, and peer reviewers will be asked to refer to these checklists when evaluating such studies. This will ensure that the authors have provided enough information for editors, peer reviewers, and readers to understand how the research was performed and to judge whether the findings are likely to be reliable.
The key reporting guidelines are
Authors are requested to include full information about the applied statistical methods and measures in their research, including justification of the appropriateness of the statistical test used (see the SAMPL guidelines for more information). Reviewers will be asked to check the statistical methods, and the submission may be sent for statistical review by specialists if considered necessary. The editors may also consult a specialist in the field of methodology.
A competing interest is anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to the journals published by ARAS PART MEDICAL INT PRESS .
A competing interest exists when professional judgment concerning a primary interest (such as patients’ welfare or the validity of research) may be influenced by a secondary interest (such as financial gain,—employment, consultancies, stock ownership or options, honoraria, patents, and paid expert—testimony or personal relationship). There is nothing unethical about a competing interest but it should be acknowledged and clearly stated. All authors must declare all competing interests in their covering letter and in the “competing interests” section upon submission. Where authors have no competing interests, the statement should read “The author(s) declare(s) that they have no competing interests with regards to authorship and/or publication of this article.” The Editor may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists.
Financial competing interests
Financial competing interests include (but are not limited to)
Non-financial competing interests
Non-financial competing interests include (but are not limited to) political, personal, ideological, academic, and intellectual competing interests.
Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should declare these as competing interests on submission. They should also adhere to the Good Publication Practice guidelines for pharmaceutical companies(GPP2), which are designed to ensure that publications are produced in a responsible and ethical manner.
The ICMJE recommends that authorship be based on the following 4 criteria:
1. Substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data.
2. Drafting the work or revising it critically for important intellectual content.
3.Final approval of the version published.
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their coauthors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be listed in an Acknowledgements section. Participation solely in the acquisition of funding, the gathering of data, technical help, writing assistance, and general supervision of the research group does not warrant authorship. Financial and material support should also be acknowledged. Please guarantee that anyone stated in the Acknowledgements section has granted its clearance for permission to be listed.
Contributor ship statement
A contributor ship statement is required for every manuscript submitted and should state who has contributed what to the planning, conduct, and reporting of the work described in the article.
Any change in authorship (ie, order, addition, and deletion of authors) after initial submission must be approved by all authors. Authors should determine the order of authorship among themselves. In addition, any alterations must be clarified to the Editor/Editor-in-chief.to an agreement about the order of authorship among themselves. In addition, any alterations must be clarified to the editor. In line with COPE guidelines, our journal requires written confirmation from all authors that they agree with any proposed changes in authorship of submission(s) or published item(s). This confirmation must be via direct email from each author. It is the corresponding author’s responsibility to ensure that all authors confirm they agree with the proposed changes. If there is disagreement amongst the authors concerning authorship and a satisfactory agreement cannot be reached, the authors must contact their institution(s) for a resolution. It is not the journal editor’s responsibility to resolve authorship disputes. A change in authorship of a published article can only be amended via publication of an Erratum.
Top Ethic Committee Approval
Inclusion of the approval letter from the relevant Ethics Committee or Institution’s Review Board regarding the research protocol and the rights of the subjects (if applicable to the study)
Top Consent Form
Attach a copy of the consent form to the letter, if applicable. Consent forms would be evaluated by the Ethics Committee and then signed by the participant.
Top RCT or NCT Registration
Emailing the letter denoting registration of RCTs or NCTs in domestic or international databases (The trial's registration number needs to be mentioned, too).Manuscripts submitted in English, must be type written, double-spaced, on good quality A4 paper, or paper of similar format. Authors are requested to reserve margins of at least 2.5cm all around the paper. Original drawings of photos, tables and figures should be furnished together with the manuscripts.
The Peer-Review System, Policy and Confidentiality
An essential part of any publication process is the peer-review process. In this process the reviewers not only give their scientific view on an article, but also recommend points for improving the quality of the article. In this way the submitted articles are refined to such an extent that are published as a logical and scientifically approved article in a journal. As a general view; it is the responsibility of the journals to offer an effective peer-review system. The aims of this publisher for peer-reviewing are of high standard and quality. Peer-review process selects papers of significant scientific interest. this publisher expects referees to not only confirm the novelty of a manuscript but also to identify the bad features and mistakes. In addition, reviewers are encouraged to suggest points for improving the submitted article. Detection of fraud and plagiarism is of utmost significance to the editors of this journal. However, the editors do not expect reviewers to identify carefully hidden ideas and intentions of deceptions in a submitted manuscript. When ever needed the submitted manuscripts are written once again. Through a team work the submitted manuscript is not only evaluated scientifically, its grammar, language and literature are also assessed. The goal of the publisher is to publish a well written, scientifically approved manuscript which is of value for the scientific community and society.
As a peer-review policy, all reviewers are requested to keep the submitted manuscripts and any associated data confidential. However if a reviewer seeks advice while assessing a manuscript, he/she must ensure that confidentiality is maintained and that the names of any such colleagues must be provided to the journal as soon as possible. This publisher makes its utmost effort to keep the content of all submitted manuscripts confidential until they are published. Although the aim of the journal is to maintain referees’ confidentiality in regard to the submitted article, it is not responsible for the conduct of reviewers.Peer review is defined as obtaining advise on individual manuscripts from reviewers experts in the field who are not part of the journal editorial staff.
Our journal accepts manuscripts report novel findings, which could result in impacts on in all fields of women’s health and reproduction science based on its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Hence, it offers an exceptionally fast publication schedule including prompt peer-review by the experts in the field and immediate publication upon acceptance. Quality and topic of submitted manuscript beside the priority of research field are the least considered criteria in each manuscript before entering in formal review process. Any type of submissions containing scientific information necessitates review process to ensure content quality.
Editorial Review and Publication
1- our journals authors will be sent notifications/Code of the manuscript’s receipt and editorial decisions by email. During the peer-reviewing process, authors can check the status of their manuscript via the Online Manuscript Submission System.
2- All submissions to the journal go through a double-blind peer-review process to ensure content quality. At the first stage, a technical editor checks format and style of manuscript to assure its compatibility with the journal guide for authors. If authors have not considered the guides, the manuscript will be sent back to authors for compatibility.
3- The manuscript will be then assigned to section editors and bio-statistician editors based on the subject area and editor-in-chief decision, for a fast pre-review screening within 1 week. Section editors check the manuscript for content quality (with a focus on methodology, originality,statically and contribution to knowledge and practice) and use of English,for prohibit of plagiarism and improve language quality article will evaluate by iThenticate belonged to Cross check as journal is a member of cross check.
The decision at this stage is fast reject, revise and re-submit, or assign to external reviewers for detailed evaluation process. Selection of external reviewers is based on their scientific background and experience, previous works, authors’ suggestion, and expertise.
4- Every attempt is made at the journal to obtain at least 2-3 strong reviews on each manuscript.
5- Editor-in-Chief receives the reviewers’ comments and sends them along with decision letter to corresponding author.
Our journals adheres to a double-blind peer-review process that is rapid, fair, and ensures the high quality of published articles.
Our journals reviewers are required to declare their conflict of interests and maintain the confidentiality about the manuscripts they review. As our journal is a rapid response journal, the review process takes between 2 to 6 months.
Managing editor receives the reviewers’ comments and sends them along with decision letter to corresponding author. Final decision on each manuscript will be made by the
After evaluation, the Editor chooses between the following decisions
2. Minor Revision
3. Major Revision
5. If the decision is Minor Revision or Major Revision, authors have 30 days to resubmit the revised manuscript. Authors may contact email address if they require an extension.
6. Upon resubmission, the Editor may choose to send the manuscript back to external reviewers, or may render a decision based on personal expertise.
It is the author’s responsibility to secure all permissions prior to publication.
Material from other sources
Any written or illustrative material that has been or will be published elsewhere must be duly acknowledged and accompanied by the written consent of the Copyright holder (this may be the publisher rather than the author). This includes your own previously published material, if you are not the copyright holder.
This Publisher follows the Committee on Publication Ethics (COPE), and also refers to the ICMJE advice on Corrections, Retractions and "Expressions of Concern" as well as on Overlapping Publications.
Corrections and retractions
Rarely, it may be necessary for ARAS PART MEDICAL INT PRESS to publish corrections to or retractions of articles published in its journals to maintain the integrity of the academic record .In line with accepted norms of the academic community, corrections to, or retractions of published articles will be made by publishing an Erratum or a Retraction article, without altering the original article in any way other than to add a prominent link to the Erratum/Retraction article. The original article remains in the public domain and the subsequent Erratum or Retraction will be widely indexed. In the exceptional event that material is considered to infringe certain rights or is defamatory, we may have to remove that material from our site and archive sites.It may be possible for minor corrections to published articles to be made by the original author(s) posting a comment on the published article. This would only be appropriate where the changes do not affect the results or conclusions of the article.
Protect of Plagiarisms
The manuscript will be then assigned to section editors and bio-statistician editors based on the subject area and editor-in-chief decision, for a fast pre-review screening within 1 week. Section editors check the manuscript for content quality (with a focus on methodology, originality, statically and contribution to knowledge and practice) and use of English, for prohibit of plagiarism and improve language quality article will be evaluated by iThenticate belonged to Cross check.Plagiarism includes, but is not limited to:
If plagiarism is detected during the peer review process, the submission may be rejected. If plagiarism is detected after publication, we reserve the right to issue a correction or retract the paper, as appropriate. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication.
-All submitted articles to our journal will be evaluated by iThenticate, two times :a) in first submission time ,b) if passed peer review process and article is in accept time.
The corresponding author will receive an e-mail alert containing a link to a web site. A working e-mail address must therefore be provided for the corresponding author. The proof can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following web site:http://www.adobe.com/products/acrobat/readstep2.html. This will enable the file to be opened, read on screen and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Authors will be charged for any major changes against the manuscript, and excessive changes may be disallowed. If a significant amount of new material is added, the paper may be re-reviewed by the Editors and re-dated. Second proofs will be sent only if justifiably requested by the author. Final proofs are read by the Editorial Office and – only in problematic cases - by the Editors.
All research involving humans (including human data and human material) and animals must have been carried out within an appropriate ethical. If there is suspicion that research has not taken place within an appropriate ethical framework, the editor may reject a manuscript and may inform third parties, for example, author(s)’ institution(s) and ethics committee(s).
In cases of proven research misconduct involving published articles, or where the scientific integrity of the article is significantly undermined, articles may be retracted.
All journals published by our publisher will follow the COPE guidelines to deal with cases of potential publication misconduct.
Arash Khaki (DVM, PhD)
Editor-in-Chief & Founder
International Journal of Women's Health and Reproductive Sciences
Tel : +447937197844 / +989143138399